The US Food and Drug Administration (FDA) has approved a new medication for the most common type of muscular dystrophy.

The US Food and Drug Administration has approved the first medication to treat Duchenne muscular dystrophy (DMD).

Medications used to treat erectile dysfunction may have another use. These medications may provide a way to help young boys with a disabling genetic disease.

Tasks as simple as walking can be difficult for patients with Duchenne muscular dystrophy. The disorder causes the body to produce too little dystrophin, a necessary protein for muscles. Without this protein, muscles continue to worsen.

Muscular dystrophy is a debilitating disease on its own. Now patients with the most serious form of the disease are learning they have increased risks of other serious diseases.

Adults need around 4,000 to 8,000 IU daily of vitamin D to maintain levels of healthful vitamin D metabolites in the range needed to reduce the risk of several diseases by about half.

Recent work from pharmacology researcher Dean Burkin may lead to better treatments for the most common form of muscular dystrophy (MD) known as Duchenne.

Acceleron Pharma, Inc. has announced receipt of a $1.5 million grant awarded from the Muscular Dystrophy Association (MDA) to support clinical studies of the therapy ACE-031.

An international team of researchers headed by an investigator from Fred Hutchinson Cancer Research Center have made a critical advance in determining the cause of a common form of muscular dystrophy.

Researchers from Florida State University and the University of Pittsburg are developing a new tool that will help those in electric wheelchairs safely navigate difficult terrain.